CA2701806A1 - Pyridine derivatives useful as glucokinase activators - Google Patents

Pyridine derivatives useful as glucokinase activators Download PDF

Info

Publication number
CA2701806A1
CA2701806A1 CA2701806A CA2701806A CA2701806A1 CA 2701806 A1 CA2701806 A1 CA 2701806A1 CA 2701806 A CA2701806 A CA 2701806A CA 2701806 A CA2701806 A CA 2701806A CA 2701806 A1 CA2701806 A1 CA 2701806A1
Authority
CA
Canada
Prior art keywords
denotes
atoms
stereoisomers
alk
ratios
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2701806A
Other languages
English (en)
French (fr)
Inventor
Lars Thore Burgdorf
Norbert Beier
Johannes Gleitz
Christine Charon
Daniel Cravo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2701806A1 publication Critical patent/CA2701806A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
CA2701806A 2007-10-09 2008-08-13 Pyridine derivatives useful as glucokinase activators Abandoned CA2701806A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07019691 2007-10-09
EP07019691.0 2007-10-09
EP08001168.7 2008-01-23
EP08001168 2008-01-23
PCT/EP2008/006649 WO2009046784A1 (en) 2007-10-09 2008-08-13 Pyridine derivatives useful as glucokinase activators

Publications (1)

Publication Number Publication Date
CA2701806A1 true CA2701806A1 (en) 2009-04-16

Family

ID=39870670

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2701806A Abandoned CA2701806A1 (en) 2007-10-09 2008-08-13 Pyridine derivatives useful as glucokinase activators

Country Status (22)

Country Link
US (1) US8420642B2 (OSRAM)
EP (1) EP2195312B1 (OSRAM)
JP (1) JP5567481B2 (OSRAM)
KR (1) KR20100090250A (OSRAM)
CN (1) CN101821264A (OSRAM)
AR (1) AR068748A1 (OSRAM)
AU (1) AU2008310097B2 (OSRAM)
BR (1) BRPI0818658A2 (OSRAM)
CA (1) CA2701806A1 (OSRAM)
CY (1) CY1113767T1 (OSRAM)
DK (1) DK2195312T3 (OSRAM)
EA (1) EA201000561A1 (OSRAM)
EC (1) ECSP10010158A (OSRAM)
ES (1) ES2399469T3 (OSRAM)
HR (1) HRP20120948T1 (OSRAM)
IL (1) IL204746A0 (OSRAM)
MX (1) MX2010003759A (OSRAM)
NZ (1) NZ585236A (OSRAM)
PL (1) PL2195312T3 (OSRAM)
PT (1) PT2195312E (OSRAM)
SI (1) SI2195312T1 (OSRAM)
WO (1) WO2009046784A1 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3078662A1 (en) 2007-09-21 2016-10-12 Array Biopharma, Inc. Pyridin-2-yl-amino-1,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CN105176930B (zh) 2010-03-31 2021-05-04 斯克里普斯研究所 重编程细胞
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012121314A1 (ja) 2011-03-09 2012-09-13 第一三共株式会社 ジピリジルアミン誘導体
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN104230892B (zh) * 2011-11-09 2016-12-07 福建海西新药创制有限公司 一组提高激酶活性的化合物及其应用
PT2821402T (pt) 2012-02-28 2019-10-02 Kotobuki Pharmaceutical Co Ltd Composto aromático heterocíclico que contém nitrogénio
AU2013205240B2 (en) 2012-03-16 2016-02-11 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
CN103664759A (zh) * 2013-12-06 2014-03-26 常熟市联创化学有限公司 一种3-羟基-2-硝基吡啶的制备方法
MY191736A (en) 2014-12-23 2022-07-13 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
EP3259256B1 (en) 2015-02-17 2022-03-09 Beijing Erai Therapeutics Co., Ltd. Compounds and methods for inducing browning of white adipose tissue
CA2981732C (en) * 2015-04-07 2024-03-12 Boris Khalfin Compositions for treating and/or preventing cell or tissue necrosis specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes thereto
WO2016164703A1 (en) * 2015-04-09 2016-10-13 Eisai R & D Management Co., Ltd. Fgfr4 inhibitors
US12030875B2 (en) 2018-09-07 2024-07-09 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
CN110568100B (zh) * 2019-09-12 2022-05-31 江西金水宝制药有限公司 一种米格列奈钙r-异构体的检测方法
AR121506A1 (es) 2020-03-03 2022-06-08 Pic Therapeutics Inc Inhibidores del eif4e y sus usos
WO2022143985A1 (zh) * 2020-12-31 2022-07-07 清华大学 吡啶-2-胺衍生物及其药物组合物和用途
EP4392422A1 (en) 2021-08-25 2024-07-03 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
JP2024532276A (ja) 2021-08-25 2024-09-05 ピク セラピューティクス， インコーポレイテッド ｅＩＦ４Ｅ阻害剤及びその使用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0178035B1 (en) * 1984-05-12 1990-01-03 FISONS plc Anti-inflammatory 1,n-diarylpyrazol-3-amines, compositions containing them and processes for their preparation
CA1305478C (en) * 1986-11-06 1992-07-21 Margaret H. Sherlock Naphthyridine and pyridopyrazine compounds and pharmaceutical usage thereof
JPH07285962A (ja) 1994-04-20 1995-10-31 Nissan Chem Ind Ltd ピリジンカルボン酸アミド誘導体
EP0790057B1 (en) 1994-11-29 2002-06-05 Hisamitsu Pharmaceutical Co., Inc. Antibacterial or bactericide comprising 2-aminothiazole derivative and salts thereof
WO1996018617A1 (en) 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase
WO1996018616A1 (en) 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
EE200200123A (et) 1999-09-10 2003-08-15 Merck & Co., Inc. Türosiinkinaasi pärssiv ühend, seda sisaldav farmatseutiline kompositsioon ning raviotstarbeline kasutamine
JP2004525069A (ja) 2000-06-15 2004-08-19 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのシクロアルキルアルカン酸
DE60108639T2 (de) 2000-07-04 2005-07-07 Neurosearch A/S Aryl- und heteroaryldiazabicycloalkane, deren zubereitung und verwendung
AU2002213467A8 (en) 2000-10-11 2009-07-30 Chemocentryx Inc Modulation of ccr4 function
PT1347971E (pt) 2000-12-21 2006-06-30 Bristol Myers Squibb Co Inibidores tiazolilicos de tirosina-cinases da familia tec
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
WO2003027100A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl pyrimidines as c17,20 lyase inhibitors
EP1336607A1 (en) * 2002-02-19 2003-08-20 Novo Nordisk A/S Amide derivatives as glucokinase activators
HUP0402309A3 (en) * 2001-12-21 2008-09-29 Novo Nordisk As Amide derivatives as glucokinase activators and pharmaceutical compositions containing them
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
EP1603905A1 (en) 2003-02-10 2005-12-14 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2004076420A1 (ja) * 2003-02-26 2004-09-10 Banyu Pharmaceutical Co., Ltd. ヘテロアリールカルバモイルベンゼン誘導体
JP2007516227A (ja) 2003-05-16 2007-06-21 アンビット バイオサイエンシス コーポレーション ピロール化合物およびその使用
WO2005021529A1 (en) * 2003-09-02 2005-03-10 Merck & Co., Inc. Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5
WO2005040112A1 (en) * 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity
CN1934100A (zh) * 2004-03-23 2007-03-21 万有制药株式会社 取代喹唑啉或吡啶并嘧啶衍生物
AU2005232753A1 (en) * 2004-04-13 2005-10-27 Astellas Pharma Inc. Polycylic thiazoles as potassium ion channel modulators
US20060019967A1 (en) 2004-07-21 2006-01-26 Su-Ying Wu SARS CoV main protease inhibitors
KR20160058972A (ko) 2004-09-02 2016-05-25 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
EP1954696B1 (en) 2005-01-19 2011-02-23 Bristol-Myers Squibb Company 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders
WO2006101740A2 (en) 2005-03-18 2006-09-28 The Regents Of The University Of California Compounds having activity in correcting mutant-cftr processing and uses thereof
US7928126B2 (en) * 2005-04-28 2011-04-19 Mitsubishi Tanabe Pharma Corporation Cyanopyridine derivative and use thereof as medicine
WO2006122011A2 (en) * 2005-05-09 2006-11-16 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
KR101346902B1 (ko) * 2005-07-09 2014-01-02 아스트라제네카 아베 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한헤테로아릴 벤즈아미드 유도체
EP1906955A2 (en) 2005-07-21 2008-04-09 Betagenon AB Use of thiazole derivatives and analogues in the treatment of cancer
JP2009503073A (ja) 2005-08-02 2009-01-29 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての５−置換チアゾール−２−イルアミノ化合物および組成物
WO2007023382A2 (en) 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
EP1948652B1 (en) * 2005-11-01 2011-08-24 Array Biopharma, Inc. Glucokinase activators
AU2006310475A1 (en) * 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides
ATE539748T1 (de) * 2006-01-27 2012-01-15 Array Biopharma Inc Glucokinaseaktivatoren
EP2543667B1 (en) * 2006-03-24 2015-01-28 Array Biopharma, Inc. A method of preparing 2-aminopyridine analogs as glucokinase activators
US8431713B2 (en) 2007-01-24 2013-04-30 Array Biopharma, Inc. 2-aminopyridine derivatives as glucokinase activators
WO2008112646A1 (en) 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyridines useful as inhibitors of protein kinases
US8362037B2 (en) * 2007-03-23 2013-01-29 Array Biopharma, Inc. 2-aminopyridine analogs as glucokinase activators
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer

Also Published As

Publication number Publication date
BRPI0818658A2 (pt) 2015-04-14
PT2195312E (pt) 2013-02-20
KR20100090250A (ko) 2010-08-13
US20100216794A1 (en) 2010-08-26
AU2008310097A1 (en) 2009-04-16
HRP20120948T1 (hr) 2012-12-31
EA201000561A1 (ru) 2010-10-29
CN101821264A (zh) 2010-09-01
ES2399469T3 (es) 2013-04-01
MX2010003759A (es) 2010-04-21
WO2009046784A1 (en) 2009-04-16
DK2195312T3 (da) 2013-01-02
AR068748A1 (es) 2009-12-02
SI2195312T1 (sl) 2013-01-31
ECSP10010158A (es) 2010-06-29
PL2195312T3 (pl) 2013-04-30
NZ585236A (en) 2012-03-30
EP2195312B1 (en) 2012-11-21
CY1113767T1 (el) 2016-07-27
JP2010540667A (ja) 2010-12-24
AU2008310097B2 (en) 2013-05-16
IL204746A0 (en) 2010-11-30
US8420642B2 (en) 2013-04-16
JP5567481B2 (ja) 2014-08-06
EP2195312A1 (en) 2010-06-16

Similar Documents

Publication Publication Date Title
AU2008310097B2 (en) Pyridine derivatives useful as glucokinase activators
EP2197849B1 (en) N- ( pyrazole- 3 -yl) -benzamide derivatives as glucokinase activators
US20100331338A1 (en) Glucokinase Activators
EP2247587B1 (en) 5-oxo-2, 3,4,5-tetrahydro-benzo[b]oxepine-4-carboxylic acid amides and 2,3-dihydro-benzo[b]oxepine-4-carboxylic acid amides for treatment and prevention of diabetes typ 1 and 2
US20110009437A1 (en) Carboxamide-heteroaryl derivatives for the treatment of diabetes
EP2231640B1 (en) Beta-amino acid derivatives for treatment of diabetes

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130812

FZDE Discontinued

Effective date: 20160815